Last updated on June 2019

Firazyr Patient Registry (Icatibant Outcome Survey - IOS)


Brief description of study

The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The data collected will be used to evaluate the safety of Firazyr (icatibant) and Cinryze (C1 inhibitor [human]) in routine clinical practice and as a data source for post-marketing investigations.

Detailed Study Description

The Icatibant Outcome Survey (IOS) is a multicenter, prospective, observational study for participants treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The entry of participants in the Icatibant Outcome Survey (IOS) is at the discretion of the physician and the participant and is not a pre-requisite for prescribing Firazyr (icatibant) or Cinryze (C1 inhibitor [human]).

Clinical Study Identifier: NCT01034969

Find a site near you

Start Over

Royal Free Hospital

London, United Kingdom
  Connect »

Royal Victoria Infirmary

Newcastle Upon Tyne, United Kingdom
  Connect »

Hospital Universitario de Bellvitge

L'Hospitalet de Llobregat, Spain
  Connect »

Campbelltown Hospital

Campbelltown, Australia
  Connect »

CHU Angers

Angers Cedex 10, France
  Connect »

Derriford Hospital

Plymouth, United Kingdom
  Connect »

Royal London Hospital

London, United Kingdom
  Connect »

Hotel Dieu

Nantes, France
  Connect »

CHUS - H. Clinico U. de Santiago

Santiago de Compostela, Spain
  Connect »

Hospital Bellvitge

L'Hospitalet de Llobregat, Spain
  Connect »

Manchester Royal Infirmary

Manchester, United Kingdom
  Connect »